News

A once-weekly treatment for deadly fungal infections from Cidara Therapeutics and Mundipharma, rezafungin demonstrated positive results in its phase 3 clinical trial.

The company believes the pill should work against the Omicron variant.

A reflection on the wins and setbacks in the second year of our pandemic, 2021.

The federal agency will provide $22 million in funding to organizations worldwide dedicated to identifying next crisis.

A novel digital pill was 98% effective in tracking daily HIV PrEP adherence.

HPV vaccination decreases cervical cancer incidence and mortality, but it is most effective in young women and girls.

Community-based models of antiretroviral therapy were as effective as facility-based care in terms of viral suppression, the study authors wrote.

Recent study results show promising new modalities.

A booster dose of the m-RNA vaccine reduced COVID-19 and the rates of severe illness across adult age groups.

Clinical and public health laboratories reported increased influenza virus detections over the past few weeks, but US cases remains comparatively low to previous flu seasons.

The CDC updated its HIV PrEP guidelines, including a recommendation that doctors talk to all sexually active adults about HIV prevention and prescribe PrEP to anyone who asks for it.

An Israeli study found that a third “booster” shot of the Pfizer-BioNTech vaccine reduced the risk of COVID-19 death by 90%.

Here is a look at some of the treatment alternatives, which can offer simpler logistics and cost considerations.

Neonatal vancomycin trial found loading with more frequent dosing over shorter time comparable to standard regimen but adversely affected hearing.

Faced with the growing threat of the Delta and Omicron variants, the FDA authorized Pfizer-BioNTech booster doses for 16- and 17-year-olds.

Urban areas in Florida had more social disorganization factors that drove HIV incidence than rural areas.

Health officials in Mississippi reported a sharp increase in COVID-19-associated deaths among pregnant women during after the Delta variant became predominant.

The FDA granted an Emergency Use Authorization to Evusheld, AstraZeneca’s long-acting monoclonal antibodies for COVID-19 prevention in high-risk individuals.

For the first time, investigators proved that a higher presence of Clostridioides difficile bacteria and toxins cause a more severe infection.

A case series observation study found a slightly higher risk of Guillain-Barre syndrome among Medicare beneficiaries within 42 days after receiving the recombinant zoster vaccine Shingrix, but no changes are needed to guidance recommending the vaccine, investigators said.

Data indicate that a third dose of the Pfizer-BioNTech vaccine, BNT162b2, increases the neutralizing antibody titers by 25-fold compared to 2 doses against the Omicron variant.

The investigational therapy, ibezapolstat, demonstrated promising results in early trials.

DARE-BV1, a gel that treats bacterial vaginosis, was granted FDA approval on its Prescription Drug User Fee Act (PDUFA) date today.

Merck announced an enrollment pause in 2 of their stage 3 clinical trials for once-monthly oral islatravir for HIV PrEP. Enrolled participants will continue receiving study medicine.

New research reveals that women who test positive for COVID-19 at the time they give birth pass along antibodies in breast milk, protecting their newborns from infection

The results are likely specific to areas without hypervirulent strains of Clostridioides difficile, such as Australia.

Parents who were themselves vaccinated against COVID-19 were more likely to vaccinate their children than parents who were not, yet even vaccinated parents showed some hesitancy.

Methamphetamine use and experienced intimate partner violence led to increased HIV viral replication in Black and Latinx men who have sex with men.